OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines by Parrington M, Arndt W, Denzler K, Holechek S, Huynh T, Wong S, Kibler K, Jacobs B, Tartaglia J, Pantaleo G

Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses by Hulot SL, Korber BT, Pantaleo G, Tartaglia J, Jacobs B, Perdiguero B, Gomez CE, Esteban M, Letvin N, Seaman MS, Haynes B, Santra S

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial by Francis D, Tartaglia J, Rerks-Ngam S, Dally L, Nitayaphan S, Ratto-Kim S, Jongrakthaitae S, Phuang-ngem Y, Chuenarom W, Schuetz A, Trichavaroj R, de Souza MS, Michael NL, Paris RM, Kim JH

European Union and EDCTP strategy in the global context: recommendations for preventive HIV/AIDS vaccines research. by Lehner, T, Hoelscher, M, Clerici, M, Gotch, F, Pedneault, L, Tartaglia, J, Gray, C, Mestecky, J, Sattentau, Q, van de Wijgert, J, Toure, C, Osmanov, S, Schmidt, R, Debre, P, Romaris, M, Hoeveler, A, Di Fabio, S

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 by Liao L, Bonsignori M, Hwang K, Moody AM, Park R, Crawford S, Chen H, Jeffries TL, Cooper M, Lu X, De R, Karasavvas N, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Tovanabutra S, Pitisuttithum P, Tartaglia J, Sinangil F, Kim J, Michael NL, Tomaras GD, Yang Z, Dai K, Pancera M, Nabel GJ, Mascola JR, Kwong PD, Pinter A, Zolla-Pazner S, Alam MS, Haynes BF